Home・Aandelen Lijst・Insulet Corp

Insulet Corp

Gesloten

SectorGezondheidszorg

132.62 -20.36

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

164.35

Max

170.86

Belangrijke statistieken
By Trading Economics
Inkomsten	-11M 91M
Verkoop	-22M 762M
K/W Sectorgemiddelde	38.551 64.641
EPS	1.42
Winstmarge	11.96
Werknemers	5,400
EBITDA	-23M 154M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+30.45% upside

Dividenden
By Acuity
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-442M 11B
Vorige openingsprijs	152.98
Vorige sluitingsprijs	132.62

Nieuwssentiment

By Acuity

83%

17%

312 / 340 Rangschikking in Healthcare

Insulet Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 19:36 UTC

Correlated Moves

Insulet Corp's shares are higher today, supported by a positive trend in the medical devices sector. The stock remains above its 20-day moving average.

31 jul 2026, 20:06 UTC

News

Insulet Corp shares are declining amid a securities class action lawsuit alleging misrepresentations about the safety of its Omnipod products.

29 jul 2026, 18:43 UTC

Insulet Corp shares are higher, driven by gains in the Health Care Equipment sub-sector. The stock remains well above its 20-day moving average.

28 jul 2026, 19:06 UTC

Correlated Moves

Insulet Corp shares are trading higher, benefiting from a significant rise in the Health Care Equipment sub-sector and ongoing momentum above their 20-day moving average.

27 jul 2026, 20:06 UTC

Insulet Corp shares are higher today, reflecting broader market trends despite an earlier pullback from a session high. No specific news was identified.

24 jul 2026, 22:26 UTC

Insulet Corp shares are lower in after-market hours, following a decline from earlier session lows. No specific company news was identified to explain the movement.

22 jul 2026, 20:01 UTC

News

Insulet Corp shares are lower amid a class action lawsuit alleging securities fraud related to safety claims about its Omnipod products.

20 jul 2026, 18:36 UTC

News

Insulet Corp is gaining today after being identified as a healthcare stock likely to deliver sustainable market-beating returns, despite ongoing legal challenges.

Peer Vergelijking

Prijswijziging

Insulet Corp Prognose

Koersdoel

By TipRanks

30.45% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 221.38 USD 30.45%

Hoogste 294 USD

Laagste 172 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Insulet Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

22 ratings

Buy

Hold

Sell

Gebaseerd op 22 analisten die aandelenratings hebben gegeven aan Insulet Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

312 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.